The federal Project Grant award R43HL176331, totaling $580,868.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The goal of this Phase I Small Business Innovation Research (SBIR) project is to develop and test a bidirectional synchronous flow-controlled ventilation system, called VentSafe, to improve oxygenation and ventilation in patients with Acute Respiratory Distress Syndrome (ARDS). The proposed VentSafe technology aims to provide gentle lung ventilation without the damaging effects of conventional ventilation, which can lead to ventilator-induced lung injury. The funding will support computational fluid dynamics analysis, prototype development, and preclinical/benchtop testing of the VentSafe system in both healthy and damaged lung models, with the objective of demonstrating improved oxygenation and ventilation compared to conventional ventilation. The award was granted to Liberandum Technologies, Inc., a for-profit manufacturer located in San Francisco, CA, with a performance period from September 1, 2024, to August 31, 2025.
Generated 3/4/25, 5:37 AM